Two studies with the early prototype non-specific PI3K inhibitor LY294002 showed that cancer cell lines with PI3K mutations or, conversely, loss of PTEN expression showed increased sensitivity to PI3K inhibition [10,132]. This evidence concerns the gene PIK3CA and cancer.